JonesTrading analyst Boris Peaker has maintained their bullish stance on CRVO stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Boris Peaker has given his Buy rating due to a combination of factors, including the pivotal Phase III program of neflamapimod in dementia with Lewy bodies, which the FDA has indicated can support approval with a single randomized trial, underscoring the significant unmet need. He notes that the company is already advancing U.S. site start-up activities using existing resources, despite a limited cash runway into the third quarter of 2026, and expects trial initiation in the second half of 2026 with topline results anticipated around mid- to late-2028.
Peaker also highlights the enhanced, stable crystal formulation at the 50 mg TID dose, which addresses prior variability in drug exposure and is supported by Phase I data. Additional upside stems from early clinical and imaging signals suggesting basal forebrain restoration, greater benefit in patients with lower pTau181 levels, and multiple Phase IIa programs in stroke recovery, nfvPPA, and ALS that could provide value-creating data readouts in 2026, all supporting his $20 price target and Buy recommendation.
In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $9.00 price target.
CRVO’s price has also changed dramatically for the past six months – from $8.300 to $3.040, which is a -63.37% drop .